Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.

Journal of translational medicine - 9 Jan 2023

Chen Dong, Su Xi, Zhu Lizhang, Jia Hao, Han Bin, Chen Haibo, Liang Qingzhuang, Hu Chenchen, Yang Hao, Liu Lisa, Li Peng, Wei Wei, Zhao Yongsheng

Abstract excerpt

BACKGROUNDS: Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent prognosis after treatment with conventional therapies such as surgical resection, thyroid hormone therapy and adjuvant radioactive iodine therapy. Unfortunately, about 20% of patients develop regional recurrence or distant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Organoids

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36624452
DOI: 10.1186/s12967-022-03848-z
PMCID: PMC9827684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.PMID 36624452Read ↗

Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.Semantic proximity Read ↗

Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of <i>Braf</i> -mutated thyroid cancer organoidsSemantic proximity Read ↗

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Development of 3D organoid models to study aggressive thyroid cancersSemantic proximity Read ↗

Development and characterization of six new human papillary thyroid carcinoma cell lines.Semantic proximity Read ↗

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

Leveraging the transcriptome-phenotype relationship to guide clinical management of papillary thyroid cancer.Semantic proximity Read ↗

Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.Semantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

Anaplastic thyroid cancer spheroids as preclinical models to test therapeuticsSemantic proximity Read ↗

Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.Semantic proximity Read ↗

BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.